Clinical Trial Update: To Compare Efficacy and Safety of CT-P39 and EU-approved Xolair in Patients With Chronic Spontaneous Urticaria [Phase 3]

View source ↗

Summary

Phase 3 trial comparing CT-P39 to EU-approved Xolair (omalizumab) in chronic spontaneous urticaria; results have been completed and posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Spontaneous Urticaria

Drugs mentioned

• CT-P39
• Xolair (omalizumab)

Snippet

Sponsor: Celltrion | Conditions: Chronic Spontaneous Urticaria | Phase 3 | Status: COMPLETED | Results posted: 2025-07-29